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Abstract
Aims/hypothesis The aim of this study was to compare IGF-
I bioactivity 36 weeks after the addition of insulin glargine
(A21Gly,B31Arg,B32Arg human insulin) or NPH insulin to
metformin therapy in type 2 diabetic patients who had poor
glucose control under metformin monotherapy.
Methods In the Lantus plus Metformin (LANMET) study,
110 poorly controlled insulin-naive type 2 diabetic patients
were randomised to receive metformin with either insulin
glargine(G+MET)orNPHinsulin(NPH+MET).Inthepresent
study, IGF-I bioactivity was measured, retrospectively, in 104
out of the 110 initially included LANMET participants before
and after 36 weeks of insulin therapy. IGF-I bioactivity was
measured using an IGF-I kinase receptor activation assay.
Results After 36 weeks of insulin therapy, insulin doses
were comparable between the G+MET (68±5.7 U/day)
and NPH+MET (71±6.2 U/day) groups (p00.68). Before
insulin therapy, circulating IGF-I bioactivity was similar
between the G+MET (134±9 pmol/l) and NPH+MET (135
±10 pmol/l) groups (p00.83). After 36 weeks, IGF-I bioac-
tivity had decreased significantly (p00.001) and did not differ
between the G+MET (116±9 pmol/l) and NPH+MET (117±
10 pmol/l) groups (p00.91). At baseline and after insulin
therapy, total IGF-I concentrations were comparable in both
groups (baseline: G+MET 13.3±1.0 vs NPH+MET 13.3±
1.0 nmol/l, p00.97; and 36 weeks: 13.4±1.0 vs 13.1±
0.9 nmol/l, p00.71). Total IGF-Iconcentration did not change
duringinsulintherapy(13.3±0.7vs13.3±0.7nmol/l,baseline
vs 36 weeks, p00.86).
Conclusions/interpretation Addition of insulin glargine or
NPH insulin to metformin monotherapy in poorly controlled
type 2 diabetic patients decreases serum IGF-I bioactivity in
a similar manner.
Keywords IGF-Ibioactivity.Insulinglargine.Insulin
therapy.NPHinsulin.TotalIGF-I.Type2diabetes
Abbreviations
AMPK AMP-activated protein kinase
G+MET Insulin glargine and metformin
HEK Human embryonal kidney
IGFBP IGF binding proteins
IGF-IR IGF-I receptor
IR Insulin receptor
KIRA Kinase receptor activation
LANMET Lantus+Metformin
NPH+MET NPH insulin and metformin
Introduction
In 2009 four observational studies were published of which
three suggested that the use of insulin glargine (A21Gly,
B31Arg,B32Arg human insulin) was associated with an
increased risk of cancer [1–4]. The US Food and Drug
Administration (FDA) reviewed these four studies and con-
cluded that ‘the evidence presented was inconclusive, due to
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DOI 10.1007/s00125-011-2435-7limitations in how the studies were designed, carried out and
in the data available for analysis’ [5].
Nevertheless these findings have raised concerns as to
whether or not insulin glargine promotes cell proliferation
and growth of neoplasms. In vitro, at high concentrations,
insulin glargine has been found to be more potent than
human insulin in stimulating the IGF-I receptor (IGF-IR)
[6–10]. By using an in-house IGF-I kinase receptor activation
(KIRA) assay, we recently confirmed that insulin glargine, at
high concentrations, is more potent than either human insulin
or insulin detemir in activating the human IGF-IR in vitro [7].
This assay uses human embryonic kidney (HEK) cells over-
expressing the human IGF-IR to quantify IGF-IR phosphory-
lation in response to stimulation by specific ligands or human
serum [11, 12]. The dose-dependent effect of insulin glargine
supports the finding of a potential link between higher doses
of insulin glargine and incidence of cancer reported in a case
control study by Mannucci et al [13].
Previously, Mayer et al have published a pilot study in
which serum from type 1 diabetic patients treated with insulin
glargine had a greater proliferative effect on MCF-7 breast
cancer cells than serum containing human insulin [14]. There
are, as yet, no studies comparing IGF-I bioactivity in type 2
diabetic patients during treatment with insulin glargine or
NPH insulin. However, such studies would help to clarify
whether insulin-mediated differences in IGF-IR activation in
vitro translate into differences in IGF-I bioactivity in vivo.
In the Lantus+Metformin (LANMET) study, the efficacy
and safety of bedtime insulin glargine was compared with
NPH insulin in poorly controlled insulin-naive type 2 diabetic
patients treated with metformin [15].
In the present study, we examined whether the addition of
insulin glargine or NPH insulin to metformin monotherapy
in poorly controlled type 2 diabetic patients induced
changes in circulating IGF-I bioactivity, as measured by
the IGF-I KIRA assay, and whether this response differed
between the two insulins.
Methods
Study design and study population
The LANMET study was a multicentre, open, randomised,
parallel-group study [15]. Briefly, in the LANMETstudy the
efficacy and safety of bedtime insulin glargine and metformin
(G+MET) was compared with NPH insulin and metformin
(NPH+MET) treatment in insulin-naive poorly controlled
type 2 diabetic patients (HbA1c 8.0% [64 mmol/mol] or
higher). The study consisted of a 4 week run-in phase and a
36 week treatment phase. It was performed at six sites in
Finland and one in the UK. The study was performed in
accordance with the Declaration of Helsinki and good clinical
practice, as described by Note for Guidance CPMP/ICH/135/
95. Approval by institutional ethics committees was obtained
for each participating site. All patients provided written
informed consent before entry into the study.
In the present study, IGF-I bioactivity was measured,
retrospectively, in participants of the LANMET study. All
LANMET participants were included from whom extra
serum samples had been collected as part of the original
protocol (104 out of 110 LANMET participants, 95% of the
total number). In addition, 41 serum samples from non-
diabetic participants (mostly spouses) were collected at the
time of the baseline visit. The latter samples were analysed
to compare IGF-I bioactivity and total IGF-I between type 2
diabetic patients and non-diabetic participants.
Since, previously, a dose-dependent increase in cancer risk
was observed for treatment with insulin glargine compared
with human insulin [1, 13], and differences between insulin
analogues and human insulin in IGF-IR activation in vitro
have only been reported at relatively high concentrations
[6–10], we also performed a sub-analysis in 40 patients, who
were treated with a mean daily insulin dose above 70 U/day
(20 patients in each treatment group).
Materials and assays
Serum IGF-I bioactivity and total serum IGF-I were mea-
sured in fasting blood samples before and after 36 weeks of
insulin treatment from type 2 diabetic patients and from
non-diabetic subjects (mostly spouses).
IGF-I KIRA bioassay The IGF-IR KIRA assay has been
previously described [11, 12]. Briefly, autophosphorylation
of tyrosine residues located within the intracellular kinase
domain of the IGF-IR is the first step in the intracellular
signalling cascade. The IGF-IR KIRA assay uses a HEK cell
line that is stably transfected with the human IGF-IR gene
(HEK IGF-IR) and quantifies phosphorylation of tyrosine
residues of the transfected IGF-IR to assess IGF-I bioactivity.
After 48 h of culture, HEK IGF-IR cells were stimulated for
15 min at 37°C with recombinant IGF-I standards (Austral
Biologicals, San Ramon, CA, USA), insulin glargine (Lantus;
sanofi-aventis, Frankfurt am Main, Germany) and NPH
insulin (Insulatard; Novo Nordisk, Bagsvaerd, Denmark).
Equimolar concentrations of IGF-I, insulin glargine and NPH
insulin were tested in a range of 100–100,000 pmol/l.
Standards were diluted in Krebs–Ringer bicarbonate
buffer adjusted to pH 7.4 by CO2 and supplemented
with 0.1% human serum albumin (Octalbine; Octopharma,
Lachen, Switzerland). After stimulation, cells were lysed.
Crude lysates were transferred to a sandwich assay. Wells were
coated with a monoclonal antibody (MAD-1) directed against
the IGF-IR (Novozymes-Gropep, Adelaide, Australia) that was
used as capture antibody at a concentration of 5.0 μg/ml. A
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1676) (R&D Systems Europe, Abingdon, UK) was used at a
concentration of 0.2 μg/ml together with streptavidin labelled
europium (DELFIA Eu-N1; PerkinElmer Life Sciences,
Groningen,theNetherlands)ataconcentrationof50pmol/las
detection antibody. Contents were read in a time-resolved
fluorimeter (Victor2 multilabel counter; PerkinElmer
Life Sciences). Assays were performed in 48 well plates
(Corning; Corning, NY, USA).
For measurements of serum IGF-I bioactivity, an IGF-I
standard, two internal control samples and two study control
samples were included on each culture plate. Serum samples
were diluted 1:10. All measurements were carried out in
duplicate. The intra-assay CV was 5.6%. The inter-assay
CVs were, respectively, 6.8% and 12.6% for the two internal
control samples.
Statistical analysis
Baseline characteristics are shown as means (or geometric
means)±SE. The Kolmogorov–S m i r n o vt e s tw a su s e dt ot e s t
normality of variables (data were considered to be normally
distributedwhenp>0.05).Fordatathatdidnotmeetthecriteria
for normality, logarithmic transformations were applied.
Pearson’scorrelationcoefficients werecalculatedtoassessthe
associations between variables. Pearson’s correlation
coefficients for IGF-I were calculated after adjustment
for age. A univariate general linear model was used to
test differences in continuous variables between the insulin
treatmentgroupsandnon-diabeticparticipants;differencesfor
total IGF-I and IGF-I bioactivity were calculated after adjust-
mentforageandsex.Differencesincategoricalvariableswere
tested by using the χ
2 test. A paired t test was used to test
differences before and after starting insulin treatment. A
p value of 0.05 or less was considered statistically significant.
Data were analysed using SPSS 17 for Windows (SPSS,
Chicago, IL, USA).
Results
In vitro measurements
Effects of insulin glargine and NPH insulin on IGF-IR
activation
Figure 1 shows that insulin glargine and NPH insulin were
equally effective in activating the IGF-IR at 100 and
1,000 pmol/l (p00.26 and p00.34, respectively). At 10,000
and 100,000 pmol/l, insulin glargine was more potent than
NPH insulin (p00.02 and p00.04, respectively) (Fig. 1).
Human recombinant IGF-I was more potent than human insu-
lin and insulin glargine over the whole range tested (Fig. 1).
In vivo measurements
Baseline characteristics
Baseline characteristics of the two patient groups did not
significantly differ from each other (Table 1). The non-
diabetic participants (matched with respect to age and sex)
were leaner and metabolically healthier compared with the
type 2 diabetic participants (Table 1).
Glycaemic control and insulin doses
Mean HbA1c concentrations were comparable in the G+MET
andNPH+METgroupsbeforeinsulintherapy(9.0±0.1%[75±
1.1 mmol/mol] vs 9.2±0.2% [77±2.2 mmol/mol] , p00.33)
and decreased similarly in both groups after insulin
therapy (7.0±0.1% [53±1.1 mmol/mol] vs 7.1±0.1%
(54±1.1 mmol/mol) [G+MET vs NPH+MET], p00.93).
In the G+MET group the mean insulin dose was 68±
5.7 U/day compared with 71±6.2 U/day in the NPH+MET
group (p00.68) and the insulin dose per kilogram was
0.69±0.05 U/kg in the G+MET group compared with
0.69±0.05 U/kg in the NPH+MET group (p00.98).
Circulating IGF-I bioactivity and total IGF-I at baseline
Mean serum IGF-I bioactivity and total IGF-I did not differ
between the two treatment groups at baseline (IGF-I bioac-
tivity: 134±9 vs 135±10 pmol/l [G+MET vs NPH+MET],
p00.83; and total IGF-I: 13.3±1.0 vs 13.3±1.0 nmol/l
[G+MET vs NPH+MET], p00.97).
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Fig. 1 Activation of the IGF-IR: comparing human IGF-I (dashed
line, black squares), insulin glargine (solid line, white squares) and
NPH insulin (dotted line, white squares). Dose–response profiles ranged
from 100 to 100,000 pmol/l. Points represent the mean value (+SEM) of
three independent experiments. *p<0.05 for human IGF-I vs insulin
glargine and NPH insulin; ***p<0.001 for human IGF-I vs insulin
glargine and NPH insulin;
†p<0.05 for insulin glargine vs NPH insulin
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total IGF-I between the two treatment groups when compar-
ing individuals using >70 U/day (118±16 pmol/l vs 129±
14 pmol/l [G+MET vs NPH+MET], p00.67; and 10.1±
1.0 nmol/l vs 10.4±1.0 nmol/l [G+MET vs NPH+MET],
p00.77).
IGF-I bioactivity was borderline significantly lower in
patients with type 2 diabetes than in non-diabetic controls
(135±7 vs 161±11 pmol/l, p00.09) (Fig. 2a). Total IGF-I
concentrations were significantly lower in patients with type
2 diabetes than in non-diabetic participants (13.3±0.7 vs
16.3±1.0 nmol/l, p00.03) (Fig. 2b).
Changes in circulating IGF-I bioactivity and total IGF-I
in response to insulin therapy
After 36weeks of insulintreatment therewerenodifferencesin
mean IGF-I bioactivity between the G+MET and the NPH
+MET groups (116±9 vs 117±10 pmol/l, p00.91) (Fig. 2b).
In addition, mean total IGF-I concentrations were not different
between the treatment groups (13.4±1.0 vs 13.1±0.9 nmol/l
[G+MET vs NPH+MET], p00.71) (Fig. 2b).
In addition, mean IGF-I bioactivity and total IGF-I did
not differ between the G+MET and the NPH+MET
groups when comparing individuals using >70 U insulin/day
(IGF-I bioactivity: 102±15 pmol/l vs 114±8 pmol/l, p0
0.63; total IGF-I: 10.8±1.1 nmol/l vs 10.5±0.9 nmol/l,
p00.23).
Mean serum IGF-I bioactivity decreased significantly
from 135±7 pmol/l at baseline to 117±6 pmol/l (p00.001)
at 36 weeks in all patients (Fig. 2a). A significant decline in
IGF-I bioactivity was also observed in individuals using >70 U
insulin/day: 123±11 pmol/l at baseline vs 108±9 pmol/l after
36 weeks of insulin therapy (p00.02).
Serum total IGF-I concentrations remained unchanged
during insulin therapy (baseline: 13.3±0.7 vs 13.3±
0.7 nmol/l after 36 weeks of insulin therapy; p00.86)
(Fig. 2b). In addition, in patients using >70 U insulin/day,
total IGF-I did not change during treatment (10.3±0.7 nmol/l
at baseline vs 10.6±0.7 nmol/l at 36 weeks, p00.24).
Interrelationships between insulin dose at 36 weeks, IGF-I
bioactivity and total IGF-I
At 36 weeks, there was a highly significant inverse relationship
between insulin dose and serum total IGF-I in both groups
(total insulin dose: G+MET group, r0−0.36, p00.007;
NPH+MET group, r0−0.41, p00.005; insulin dose/kg:
Table 1 Baseline characteristics of diabetic patients randomised to the G+MET group or NPH+MET group within the original LANMET study
and of diabetic patients (in the G+MET or NPH group) and non-diabetic participants analysed in the present study
Characteristic LANMET study
G+MET
a
LANMET study
NPH+MET
a
G+MET
group
b
NPH+MET
group
b
Non-diabetic
participants
b
p value
c p value
d
Patients (n) 6 14 95 7 4 7 4 1 ––
Sex (male/female) 38/23 32/17 35/22 31/16 19/22 0.63 0.06
Age (years)
e 56±1 57±1 56.0±1.2 56.7±1.2 56.6±1.3 0.71 0.88
Metformin dose (g/day) 2.28±0.06 2.19±0.05 2.16±0.05 2.23±0.06 – 0.38 –
Previous sulfonylurea (%) 79 86 81 89 – 0.28
Previous ACE inhibitor (%) 57 55 53 49 – 0.84
Previous beta-blocker or thiazide (%) 71 63 67 59 – 0.54
Weight (kg) 92.0±2.4 94.4±1.2 92.3±2.4 95.5±2.6 82.1±3.1 0.36 0.001
BMI (kg/m
2)
e 31.3±0.7 32.0±0.8 31.0±0.7 31.9±0.8 27.8±0.7 0.35 <0.001
HbA1c (%)
e 9.5±0.1 9.6±0.1 9.0±0.1 9.2±0.2 5.4±0.1 0.33 <0.001
HbA1c (mmol/mol)
e 80±1.1 81±1.1 75±1.1 77±2.2 36±1.1
FPG (mmol/l)
a 13.0±0.3 12.9±0.3 12.3±0.3 11.9±0.4 5.5±0.1 0.43 <0.001
C-peptide (nmol/l) 0.98±0.04 1.00±0.07 1.0±0.04 1.0±0.07 0.7±0.06 0.86 <0.001
Serum TG (mmol/l)
a 2.3±0.2 2.5±0.2 2.0±0.2 2.2±0.2 1.2±0.1 0.17 <0.001
HDL-cholesterol (mmol/l)
a 1.18±0.04 1.18±0.04 1.2±0.04 1.1±0.03 1.5±0.07 0.25 <0.001
LDL-cholesterol (mmol/l)
a 2.8±0.1 2.9±0.1 2.7±0.1 2.8±0.1 3.4±0.1 0.40 <0.001
Data are presented as mean±SE
aValues from the original LANMET study;
bvalues from the present study
cp values are shown for differences between the G+MET group vs the NPH+MET group in the present study
dp values are shown for differences between diabetic participants vs non-diabetic participants in the present study
eGeometric mean
FPG, fasting plasma glucose; TG, triacylglycerol
Diabetologia (2012) 55:1186–1194 1189G+MET group r0−0.33, p00.01; NPH+MET group r0−0.36,
p00.02), (Fig. 3). There was no significant correlation between
insulin dose and IGF-I bioactivity (total insulin dose: G+MET
group r0−0.23, p00.10; NPH+MET group r0−0.08, p00.58;
insulin dose/kg: G+MET group r0−0.17, p00.22; NPH+MET
group r0−0.08, p00.58), at 36 weeks.
Discussion
Insulin glargine has previously been found to be more
potent than human insulin in activating the IGF-IR in
vitro. However, this effect has only been observed at high
(supra-physiological) insulin concentrations [6–10]. Indeed,
in the present study, by using our in-house IGF-IR KIRA
assay, we confirmed that at high concentrations insulin
glargine is more potent than NPH insulin in activating
the IGF-IR in vitro. However, in contrast to these in
vitro findings, serum from type 2 diabetic patients who
were treated for 36 weeks with metformin and insulin
glargine induced similar IGF-IR activation compared
with that of patients treated with metformin and NPH
insulin for 36 weeks. Moreover, after 36 weeks of
insulin treatment, IGF-I bioactivity decreased significantly in
both groups. Total IGF-I concentrations were similar in both
groups at baseline and remained unchanged during insulin
therapy.
A sub-analysis was performed in patients who had used
high mean daily insulin doses (above 70 U/day) in order to
address a previous observation of a dose-dependent increase
in cancer risk for insulin glargine treatment. However, also
in this sub-group, IGF-I bioactivity was similar in both
groups after 36 weeks of therapy and had also decreased
significantly, whereas total IGF-I remained unchanged. In
addition, we found a significant inverse relationship between
insulindoseandtotalIGF-I,but notforinsulindoseandIGF-I
bioactivity.Therefore,althoughwe didnotstudythe effects of
insulin therapy on cancer incidence, our findings do not
support the idea that insulin therapy raises cancer risk through
an increase in IGF-I bioactivity.
In the present study insulin concentrations were not
measured because of the inability of commercially available
serum insulin assays to accurately measure insulin glargine.
However, in a previous study, in which type 2 diabetic
patients were treated with insulin glargine, a mean dose
of 0.43 U kg
-1 day
-1 resulted in mean free plasma insulin
concentrations of 126 pmol/l [16]. In another study, the max-
imalconcentrationofserum insulin ataninsulinglarginedose
of 1.4 U kg
-1 day
-1 was around 700 pmol/l [17]. Extrapolating
theseresultstothemaximalinsulindosesthatwereusedinour
study (1.7 U kg
-1 day
-1), it seems unlikely that free plasma
insulin concentrations exceeded 500–850 pmol/l during
treatmentwithinsulinglargine.Moreover,ithasbeenreported
that insulin glargine concentrations measured by regular insu-
lin immunoassays are usually overestimated by ~30% [18].
Taken together this suggests that in vivo concentrations of
insulin glargine are unlikely to reach concentrations at which
we and others have observed differences in IGF-IR activation
in vitro. The latter could be an explanation of why we did not
observe differences in IGF-I bioactivity between the two
treatment arms. In addition, after subcutaneous injection, in-
sulinglargineispartiallydegradedintotwobioactiveproducts
(M1 and M2) [19]. The M1 degradation product has been
shown to have less mitogenic potency than insulin glargine
itself and even less potency than human insulin [6]. These
findings raise the possibility that insulin glargine would be
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Fig. 2 a IGF-I bioactivity (pmol/l) in non-diabetic participants (white
box) at baseline and in diabetic participants in the G+MET group (dark
grey boxes) and in the NPH+MET group (light grey boxes) at baseline
and after 36 weeks of insulin treatment. The line in the boxes
represents the mean of the data. The boxes extend from the 25th
percentile to the 75th percentile values and the whiskers show the mini-
mum and maximum values for each group.
†p00.09 for IGF-I bioactivity
in non-diabetic participants at baseline vs IGF-I bioactivity in diabetic
patients at baseline. ***p<0.001 for IGF-I bioactivity at baseline vs IGF-I
bioactivity at 36 weeks in all patients. b Total IGF-I (nmol/l) in non-
diabetic participants (white box) at baseline and in diabetic participants in
the G+MET group (dark grey boxes) and in the NPH+MET group (light
grey boxes) at baseline and after 36 weeks of insulin treatment. *p00.03
for total IGF-I in non-diabetic participants at baseline vs total IGF-I in
diabetic patients at baseline
1190 Diabetologia (2012) 55:1186–1194less mitogenic in vivo than it is in vitro and could be another
explanationforthe absenceofdifferencesinIGF-Ibioactivity
between the two treatment arms. Direct measurement of
circulating concentrations of insulin glargine and its metabo-
lites during insulin therapy would be helpful in clarifying this
latter possibility [20].
The observed decline in IGF-I bioactivity during insulin
therapy in both treatment arms is in line with a recent study,
which showed that acute hyperinsulinemia suppressed IGF-I
bioactivity, whereas total serum IGF-I did not change [21].
The decrease in circulating IGF-I bioactivity in the latter
study was attributed to insulin-mediated effects on circulating
IGF binding proteins (IGFBPs): insulin suppressed IGFBP-4
and IGFBP-1 and increased IGFBP-2 concentrations [21]. In
addition,ithasbeenreportedthatIGFBP-3proteaseactivityis
increased in untreated diabetic patients and decreases after
several days of insulin treatment [22, 23]. The latter effect
may also have contributed to the observed decrease in IGF-I
bioactivity during insulin treatment in our study.
Atbaseline,IGF-Ibioactivitywasslightlylowerinthe type
2 diabetic patients than in the leaner non-diabetic participants.
Although this comparison was not the primary aim of our
study, this finding is in line with previous data comparing
patients with type 2 diabetes with those with impaired or
normal glucose tolerance [24]. One mechanism responsible
for lower IGF-I bioactivity in the diabetic patients could be
chronic hyperinsulinaemia (C-peptide levels were 50%
higher in the type 2 diabetic patients than in non-
diabetic participants), since it has been suggested that
prolonged insulin exposure inhibits GH-induced signalling
at both receptor and postreceptor level in the liver [25].
Total IGF-I concentrations were significantly lower in the
diabetic patients than in the non-diabetic participants. In
previous studies, total IGF-I concentrations in type 2 diabetic
patients have been reported to be lower, similar to, or higher
than in non-diabeticcontrol participants [26]. Different results
in these studies could be due to variability in insulin concen-
trations because of different treatment regimens and/or varia-
tion in insulin sensitivity in type 2 diabetes [26]. Another
factor may be that in many previous studies immunoassays
have been used that may not have accurately measured IGF-I
levels as a result of problems with assay standardisation and/
or with assay methodology [27].
It has been suggested that the IGF-I KIRA assay is more
sensitive than the commonly used total IGF-I immunoassays
in detecting differences in clinical state [28]. Moreover, the
IGF-I KIRA assay seems to be superior to commonly used
IGF-I immunoassays in monitoring therapeutic interven-
tions [28]. Thus the measurement of IGF-I bioactivity could
be an important tool to clarify controversies that exist about
the precise role of the IGF-I system in diabetes.
Our data do not support the idea that the use of insulin
glargine in type 2 diabetes leads to higher circulating IGF-I
bioactivity in vivo, compared with NPH insulin. Our findings
are in line with a recently published paper in which, in an
animal model of type 2 diabetes, no differences were demon-
stratedinthedegreeofcolonicepithelialproliferationbetween
animals treated with insulin glargine or NPH insulin [29].
Nevertheless, in that study insulin treatment did result
in a higher degree of colonic epithelial proliferation, thereby
pointing towards the potential mitogenic properties of all
insulins, irrespective of type [29].
It is important to emphasise that, with the IGF-I KIRA,
phosphorylation of the tyrosine residues within the ß-subunits
of the IGF-IR is quantified, but it cannot be assessed whether
activation of the IGF-IR by an insulin analogue results in a
normal (i.e. balanced metabolic and mitogenic) activity at
cellular level in vivo. The IGF-IR may differentially elicit
biological effects and intracellular signalling upon binding
of different insulin analogues. In this respect it has been
suggested that intracellular signalling induced by insulin
analogues differs from human insulin: insulin analogues
preferentially activate the extracellular signal-related ki-
nase (ERK) pathway rather than the AKT pathway [30].
Thus there is still a chance that (subtle) differences in the
molecular structure of insulin analogues may affect in
vivo signalling at the postreceptor level and thereby
induce an abnormal metabolic:mitogenic ratio (e.g. an
increased activation of the IGF-IR may inhibit apoptosis
and promote cancer by increasing cell proliferation [20]).
It should be stressed that in this study the decline in
serum IGF-I bioactivity during insulin treatment was found
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Fig. 3 Correlations between
daily insulin dose and IGF-I
bioactivity (a) and total IGF-I
(b) in the G+MET (black dots)
and NPH+MET (white dots)
groups. a G+MET r0−0.17,
p00.22; NPH+MET r0−0.08,
p00.58. b G+MET r0−0.33,
p00.01; NPH+MET r0−0.36,
p00.02
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Metformin is a widely prescribed glucose-lowering drug that
is recommended as the initial pharmacological therapy,
together with lifestyle interventions, for type 2 diabetes
[31]. All patients in our study had already been treated
with metformin for at least 3 months before being
randomly assigned to either insulin glargine or NPH insulin
therapy. Several studies have shown that metformin treatment
is associated with a lower cancer risk [4, 32, 33]. Therefore,
concomitant metformin use has been suggested to be a poten-
tial confounder when it comes to estimating the risks of insulin
therapy for cancer [34]. However, in our study we merely
addressed IGF-I bioactivity and not cancer incidence. The
potential mechanisms of a potential anticancer effect of
metformin seem to be very complex [35]. Metformin
reverses endogenous hyperinsulinaemia through its effects on
glucose homeostasis and therefore may directly have antipro-
liferative effects [36]. Indirectly, a reduction of endogenous
insulin levels may also lower IGF-I bioactivity by improving
insulin sensitivity [37]. Most importantly, metformin activates
the AMP-activated protein kinase (AMPK) signalling pathway
[35]. One of the major growth regulatory pathways controlled
by AMPK is the mammalian target of rapamycin (mTOR)
pathway and its downstream substrates [38, 39]. In addition,
in NIH-3T3 cells, stimulation of AMPK inhibits the ability of
IGF-I to activate ras and its downstream targets, but phos-
phorylation of the activated IGF-IR appeared to be unaffected
by this increase in AMPK activity [40]. Thus, metformin
seems to interfere with IGF-I signalling at the postreceptor
level and not at the receptor level. Nevertheless, we cannot
exclude the possibility that concomitant metformin therapy
has influenced our findings.
Finally, a few limitations of our study need to be addressed.
First of all theLANMETstudy wasnot primarily designedand
performed to study the effects of insulin therapy on IGF-I
bioactivity and/or cancer incidence. We could only study
IGF-I bioactivity during a relatively short follow-up period
and in participants who were already treated with metformin.
Therefore the post-hoc analysis in our study was inevitable.
Nevertheless, again, we did not study cancer incidence. In
addition, we would like to underline that, after 36 weeks of
insulin treatment, there was no difference in IGF-I bioactivity
between participants treated with insulin glargine or NPH
insulin.
Second, as for all in vitro systems, the IGF-I KIRA bioas-
say does not mimic the exact in vivo conditions. Responses to
insulin and insulin analogues in vivo are far more complex
and are mediated by insulin receptors next to IGF-IRs and
possibly also by hybrid receptors, which are widely expressed
on normal tissues and often aberrantly expressed in cancer
cells [41]. However, although the precise biological role of
these hybrids is still unclear, functional studies have demon-
strated that hybrid receptors behave more like IGF-IRs than
IRs [41] and therefore, in this context, the effects we found
on IGF-IR phosphorylation could be important in vivo.
In conclusion, circulating IGF-I bioactivity was similar in
poorly controlled type 2 diabetic patients who had been trea-
ted for 36 weeks with either insulin glargine or NPH insulin
combined with metformin. Moreover, insulin treatment de-
creased IGF-I bioactivity. In addition, there was a significant
inverse relationship between insulin dose and total IGF-I.
Therefore, our data do not indicate increased IGF-IR signal-
ling in type 2 diabetic patients treated with insulin glargine.
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